Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Duzhibao (also referred to as Zu zhibao in clinical registry records) is an oral liquid formulation, likely a botanical extract or Traditional Chinese Medicine (TCM) product, currently being investigated for its potential to modulate postprandial blood glucose and insulin levels. It is being evaluated in a clinical trial (ChiCTR2500102977) sponsored by Shanghai Fengxian Central Hospital, which focuses on adults with type 2 diabetes mellitus. The study is an acute randomized, placebo-controlled, crossover trial that assesses the immediate effects of the liquid during a mixed meal tolerance test (MMTT). While the specific active ingredients and molecular targets are not disclosed in the registry, the product is positioned as a therapeutic intervention for glycemic management in diabetic patients, potentially through the modulation of glucose absorption or insulin sensitivity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Duzhibao.